Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.112062
Revised: August 17, 2025
Accepted: October 28, 2025
Published online: December 26, 2025
Processing time: 160 Days and 3.4 Hours
Myocardial infarction (MI) occupies a very high mortality and morbidity rate, and the search for effective pharmacological treatments has far-reaching implications for clinical research.
To explore the protective effects of Mongolian medicine Agari-5 on rats with MI.
Sprague-Dawley rats were used, and both the Agari-5 and model groups had their coronary arteries clamped to induce MI. Proteomics was used to research the potential mechanism of action while ELISA, hematoxylin and eosin, and Masson’s staining were used to preliminarily investigate the protective impact of Agari-5 on rats with MI.
The current study has shown that Agari-5 might enhance cardiac function indicators, including echocardiography results of rats and creatine kinase, creatine kinase isoenzyme, and lactate dehydrogenase, in rats that had MI. According to the results of pathological staining, Agari-5 may lessen inflammatory cell infiltration and cardiomyocyte fibrosis, among other things. The proteome analysis revealed that there were 60 distinct proteins in total, four of which were asso
Potential therapeutic effects of Agari-5 for MI and its mechanism of action may be related to PSAT1, PDK1, SMAD4, and SDF2.
Core Tip: We demonstrated that myocardial infarction (MI) rats treated with Agari-5 expressed similar levels of SDF2, PDK1, SMAD4, and PSAT1 as the control group, suggesting that these proteins be important targets influenced by Agari-5. Through proteomic analysis the research delved deeper into the protective mechanisms of Mongolian traditional medicine formulas, finding that these traditional formulas may protect MI rats through the regulation of multiple protein targets and molecular mechanisms, such as multicomponent interactions and synergistic effects, providing a new direction for research on national medicines and offering a reference for clinical treatments of cardiovascular diseases.
